toxoflavin has been researched along with Hepatocellular Carcinoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chua, MS; Grepper, S; So, S; Wei, W | 1 |
1 other study(ies) available for toxoflavin and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; beta Catenin; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclin D1; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genes, myc; Hepatocytes; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Perylene; Pyrimidinones; Random Allocation; Signal Transduction; Survivin; Transcription Factor 4; Transcription Factors; Triazines; Wnt Proteins; Xenograft Model Antitumor Assays | 2010 |